Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Unraveling the Role of Angiogenesis in Cancer Ecosystems.

Zuazo-Gaztelu I, Casanovas O.

Front Oncol. 2018 Jul 2;8:248. doi: 10.3389/fonc.2018.00248. eCollection 2018. Review.

2.

TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence.

Puig I, Tenbaum SP, Chicote I, Arqués O, Martínez-Quintanilla J, Cuesta-Borrás E, Ramírez L, Gonzalo P, Soto A, Aguilar S, Eguizabal C, Caratù G, Prat A, Argilés G, Landolfi S, Casanovas O, Serra V, Villanueva A, Arroyo AG, Terracciano L, Nuciforo P, Seoane J, Recio JA, Vivancos A, Dienstmann R, Tabernero J, Palmer HG.

J Clin Invest. 2018 Jun 26. pii: 96393. doi: 10.1172/JCI96393. [Epub ahead of print]

3.

Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR study.

Capdevila J, Teulé A, Barriuso J, Castellano D, Lopez C, Manzano JL, Alonso V, García-Carbonero R, Dotor E, Matos I, Custodio A, Casanovas O, Salazar R; EVERLAR study investigators.

Oncologist. 2018 May 23. pii: theoncologist.2017-0622. doi: 10.1634/theoncologist.2017-0622. [Epub ahead of print]

PMID:
29794066
4.

ALK1 Loss Results in Vascular Hyperplasia in Mice and Humans Through PI3K Activation.

Alsina-Sanchís E, García-Ibáñez Y, Figueiredo AM, Riera-Domingo C, Figueras A, Matias-Guiu X, Casanovas O, Botella LM, Pujana MA, Riera-Mestre A, Graupera M, Viñals F.

Arterioscler Thromb Vasc Biol. 2018 May;38(5):1216-1229. doi: 10.1161/ATVBAHA.118.310760. Epub 2018 Feb 15.

PMID:
29449337
5.

A Role for CXCR4 in Peritoneal and Hematogenous Ovarian Cancer Dissemination.

Figueras A, Alsina-Sanchís E, Lahiguera Á, Abreu M, Muinelo-Romay L, Moreno-Bueno G, Casanovas O, Graupera M, Matias-Guiu X, Vidal A, Villanueva A, Viñals F.

Mol Cancer Ther. 2018 Feb;17(2):532-543. doi: 10.1158/1535-7163.MCT-17-0643. Epub 2017 Nov 16.

PMID:
29146630
6.

Angiogenesis and Metabolism: Entwined for Therapy Resistance.

Jiménez-Valerio G, Casanovas O.

Trends Cancer. 2017 Jan;3(1):10-18. doi: 10.1016/j.trecan.2016.11.007. Epub 2016 Dec 26. Review.

PMID:
28718423
7.

Pre-clinical longitudinal monitoring of hemodynamic response to anti-vascular chemotherapy by hybrid diffuse optics.

Farzam P, Johansson J, Mireles M, Jiménez-Valerio G, Martínez-Lozano M, Choe R, Casanovas O, Durduran T.

Biomed Opt Express. 2017 Apr 19;8(5):2563-2582. doi: 10.1364/BOE.8.002563. eCollection 2017 May 1.

8.

Sprouting strategies and dead ends in anti-angiogenic targeting of NETs.

Carrasco P, Zuazo-Gaztelu I, Casanovas O.

J Mol Endocrinol. 2017 Jul;59(1):R77-R91. doi: 10.1530/JME-17-0029. Epub 2017 May 3. Review.

9.

Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition.

Mateo F, Arenas EJ, Aguilar H, Serra-Musach J, de Garibay GR, Boni J, Maicas M, Du S, Iorio F, Herranz-Ors C, Islam A, Prado X, Llorente A, Petit A, Vidal A, Català I, Soler T, Venturas G, Rojo-Sebastian A, Serra H, Cuadras D, Blanco I, Lozano J, Canals F, Sieuwerts AM, de Weerd V, Look MP, Puertas S, García N, Perkins AS, Bonifaci N, Skowron M, Gómez-Baldó L, Hernández V, Martínez-Aranda A, Martínez-Iniesta M, Serrat X, Cerón J, Brunet J, Barretina MP, Gil M, Falo C, Fernández A, Morilla I, Pernas S, Plà MJ, Andreu X, Seguí MA, Ballester R, Castellà E, Nellist M, Morales S, Valls J, Velasco A, Matias-Guiu X, Figueras A, Sánchez-Mut JV, Sánchez-Céspedes M, Cordero A, Gómez-Miragaya J, Palomero L, Gómez A, Gajewski TF, Cohen EEW, Jesiotr M, Bodnar L, Quintela-Fandino M, López-Bigas N, Valdés-Mas R, Puente XS, Viñals F, Casanovas O, Graupera M, Hernández-Losa J, Ramón Y Cajal S, García-Alonso L, Saez-Rodriguez J, Esteller M, Sierra A, Martín-Martín N, Matheu A, Carracedo A, González-Suárez E, Nanjundan M, Cortés J, Lázaro C, Odero MD, Martens JWM, Moreno-Bueno G, Barcellos-Hoff MH, Villanueva A, Gomis RR, Pujana MA.

Oncogene. 2017 May 11;36(19):2737-2749. doi: 10.1038/onc.2016.427. Epub 2016 Dec 19.

10.

Antiangiogenic resistance via metabolic symbiosis.

Jiménez-Valerio G, Casanovas O.

Mol Cell Oncol. 2016 Jul 14;3(5):e1211979. eCollection 2016.

11.

Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action.

Duran I, Lambea J, Maroto P, González-Larriba JL, Flores L, Granados-Principal S, Graupera M, Sáez B, Vivancos A, Casanovas O.

Target Oncol. 2017 Feb;12(1):19-35. doi: 10.1007/s11523-016-0463-4. Review.

PMID:
27844272
12.

Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors.

Soler A, Figueiredo AM, Castel P, Martin L, Monelli E, Angulo-Urarte A, Milà-Guasch M, Viñals F, Baselga J, Casanovas O, Graupera M.

Clin Cancer Res. 2016 Dec 1;22(23):5805-5817. Epub 2016 May 25.

13.

Translational research in neuroendocrine tumors: pitfalls and opportunities.

Capdevila J, Casanovas O, Salazar R, Castellano D, Segura A, Fuster P, Aller J, García-Carbonero R, Jimenez-Fonseca P, Grande E, Castaño JP.

Oncogene. 2017 Apr 6;36(14):1899-1907. doi: 10.1038/onc.2016.316. Epub 2016 Sep 19. Review.

PMID:
27641330
14.

The truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients.

Gahete MD, Rincón-Fernández D, Durán-Prado M, Hergueta-Redondo M, Ibáñez-Costa A, Rojo-Sebastián A, Gracia-Navarro F, Culler MD, Casanovas O, Moreno-Bueno G, Luque RM, Castaño JP.

Oncotarget. 2016 Sep 13;7(37):60110-60122. doi: 10.18632/oncotarget.11076.

15.

The TGFβ pathway stimulates ovarian cancer cell proliferation by increasing IGF1R levels.

Alsina-Sanchis E, Figueras A, Lahiguera Á, Vidal A, Casanovas O, Graupera M, Villanueva A, Viñals F.

Int J Cancer. 2016 Oct 15;139(8):1894-903. doi: 10.1002/ijc.30233. Epub 2016 Jun 25.

16.

Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients.

Jiménez-Valerio G, Martínez-Lozano M, Bassani N, Vidal A, Ochoa-de-Olza M, Suárez C, García-Del-Muro X, Carles J, Viñals F, Graupera M, Indraccolo S, Casanovas O.

Cell Rep. 2016 May 10;15(6):1134-43. doi: 10.1016/j.celrep.2016.04.015. Epub 2016 Apr 28.

17.

Scanning, non-contact, hybrid broadband diffuse optical spectroscopy and diffuse correlation spectroscopy system.

Johansson JD, Mireles M, Morales-Dalmau J, Farzam P, Martínez-Lozano M, Casanovas O, Durduran T.

Biomed Opt Express. 2016 Jan 15;7(2):481-98. doi: 10.1364/BOE.7.000481. eCollection 2016 Feb 1.

18.

Antiangiogenic Resistance: Novel Angiogenesis Axes Uncovered by Antiangiogenic Therapies Research.

Jiménez-Valerio G, Casanovas O.

Curr Drug Targets. 2016;17(15):1728-1734. Review.

PMID:
26926466
19.

MicroRNA-497 impairs the growth of chemoresistant neuroblastoma cells by targeting cell cycle, survival and vascular permeability genes.

Soriano A, París-Coderch L, Jubierre L, Martínez A, Zhou X, Piskareva O, Bray I, Vidal I, Almazán-Moga A, Molist C, Roma J, Bayascas JR, Casanovas O, Stallings RL, Sánchez de Toledo J, Gallego S, Segura MF.

Oncotarget. 2016 Feb 23;7(8):9271-87. doi: 10.18632/oncotarget.7005.

20.

PTEN mediates Notch-dependent stalk cell arrest in angiogenesis.

Serra H, Chivite I, Angulo-Urarte A, Soler A, Sutherland JD, Arruabarrena-Aristorena A, Ragab A, Lim R, Malumbres M, Fruttiger M, Potente M, Serrano M, Fabra À, Viñals F, Casanovas O, Pandolfi PP, Bigas A, Carracedo A, Gerhardt H, Graupera M.

Nat Commun. 2015 Jul 31;6:7935. doi: 10.1038/ncomms8935.

21.

Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE).

Grande E, Capdevila J, Castellano D, Teulé A, Durán I, Fuster J, Sevilla I, Escudero P, Sastre J, García-Donas J, Casanovas O, Earl J, Ortega L, Apellaniz-Ruiz M, Rodriguez-Antona C, Alonso-Gordoa T, Díez JJ, Carrato A, García-Carbonero R.

Ann Oncol. 2015 Sep;26(9):1987-93. doi: 10.1093/annonc/mdv252. Epub 2015 Jun 10.

PMID:
26063633
22.

A novel role for an RCAN3-derived peptide as a tumor suppressor in breast cancer.

Martínez-Høyer S, Solé-Sánchez S, Aguado F, Martínez-Martínez S, Serrano-Candelas E, Hernández JL, Iglesias M, Redondo JM, Casanovas O, Messeguer R, Pérez-Riba M.

Carcinogenesis. 2015 Jul;36(7):792-9. doi: 10.1093/carcin/bgv056. Epub 2015 Apr 26.

PMID:
25916653
23.

Multi-target angiokinase inhibitors to fight resistance.

Casanovas O, Salazar R, Tabernero J.

Cell Cycle. 2014;13(17):2649-50. doi: 10.4161/15384101.2014.954216. No abstract available.

24.

Haematopoietic focal adhesion kinase deficiency alters haematopoietic homeostasis to drive tumour metastasis.

Batista S, Maniati E, Reynolds LE, Tavora B, Lees DM, Fernandez I, Elia G, Casanovas O, Lo Celso C, Hagemann T, Hodivala-Dilke K.

Nat Commun. 2014 Oct 1;5:5054. doi: 10.1038/ncomms6054.

PMID:
25270220
25.

Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype.

Larrayoz M, Pio R, Pajares MJ, Zudaire I, Ajona D, Casanovas O, Montuenga LM, Agorreta J.

EMBO Mol Med. 2014 Apr;6(4):539-50. doi: 10.1002/emmm.201303214. Epub 2014 Feb 5.

26.

Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets.

Capdevila J, Meeker A, García-Carbonero R, Pietras K, Astudillo A, Casanovas O, Scarpa A.

Cancer Metastasis Rev. 2014 Mar;33(1):345-51. doi: 10.1007/s10555-013-9468-y. Review.

PMID:
24375391
27.

Antiangiogenic therapies: going beyond their limits.

Moserle L, Jiménez-Valerio G, Casanovas O.

Cancer Discov. 2014 Jan;4(1):31-41. doi: 10.1158/2159-8290.CD-13-0199. Epub 2013 Dec 19. Review.

28.

The PDGFRβ-AKT pathway contributes to CDDP-acquired resistance in testicular germ cell tumors.

Juliachs M, Muñoz C, Moutinho CA, Vidal A, Condom E, Esteller M, Graupera M, Casanovas O, Germà JR, Villanueva A, Viñals F.

Clin Cancer Res. 2014 Feb 1;20(3):658-67. doi: 10.1158/1078-0432.CCR-13-1131. Epub 2013 Nov 25.

29.

Inhibition of the p110α isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis.

Soler A, Serra H, Pearce W, Angulo A, Guillermet-Guibert J, Friedman LS, Viñals F, Gerhardt H, Casanovas O, Graupera M, Vanhaesebroeck B.

J Exp Med. 2013 Sep 23;210(10):1937-45. doi: 10.1084/jem.20121571. Epub 2013 Sep 16.

30.

Effectivity of pazopanib treatment in orthotopic models of human testicular germ cell tumors.

Juliachs M, Vidal A, Del Muro XG, Piulats JM, Condom E, Casanovas O, Graupera M, Germà JR, Villanueva A, Viñals F.

BMC Cancer. 2013 Aug 10;13:382. doi: 10.1186/1471-2407-13-382.

31.

Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells.

Vives M, Ginestà MM, Gracova K, Graupera M, Casanovas O, Capellà G, Serrano T, Laquente B, Viñals F.

Int J Cancer. 2013 Nov 15;133(10):2464-72. doi: 10.1002/ijc.28259. Epub 2013 Jun 4.

32.

Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches.

Oberg K, Casanovas O, Castaño JP, Chung D, Delle Fave G, Denèfle P, Harris P, Khan MS, Kulke MH, Scarpa A, Tang LH, Wiedenmann B.

Clin Cancer Res. 2013 Jun 1;19(11):2842-9. doi: 10.1158/1078-0432.CCR-12-3458. Epub 2013 Mar 4. Review.

33.

Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination.

Anderberg C, Cunha SI, Zhai Z, Cortez E, Pardali E, Johnson JR, Franco M, Páez-Ribes M, Cordiner R, Fuxe J, Johansson BR, Goumans MJ, Casanovas O, ten Dijke P, Arthur HM, Pietras K.

J Exp Med. 2013 Mar 11;210(3):563-79. doi: 10.1084/jem.20120662. Epub 2013 Feb 11.

34.

ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor.

Juliachs M, Castillo-Ávila W, Vidal A, Piulats JM, Garcia Del Muro X, Condom E, Hernández-Losa J, Teixidó C, Pandiella A, Graupera M, Casanovas O, Germà JR, Villanueva A, Viñals F.

Int J Cancer. 2013 Jul;133(1):235-46. doi: 10.1002/ijc.28009. Epub 2013 Feb 12.

35.

Anti-angiogenesis and metastasis: a tumour and stromal cell alliance.

Moserle L, Casanovas O.

J Intern Med. 2013 Feb;273(2):128-37. doi: 10.1111/joim.12018. Review.

36.

Progeny of Lgr5-expressing hair follicle stem cell contributes to papillomavirus-induced tumor development in epidermis.

da Silva-Diz V, Solé-Sánchez S, Valdés-Gutiérrez A, Urpí M, Riba-Artés D, Penin RM, Pascual G, González-Suárez E, Casanovas O, Viñals F, Paramio JM, Batlle E, Muñoz P.

Oncogene. 2013 Aug 8;32(32):3732-43. doi: 10.1038/onc.2012.375. Epub 2012 Sep 3.

PMID:
22945646
37.

Relevance of angiogenesis in neuroendocrine tumors.

Teulé A, Casanovas O.

Target Oncol. 2012 Jun;7(2):93-8. doi: 10.1007/s11523-012-0217-x. Epub 2012 May 17. Review.

PMID:
22592949
38.

Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice.

Maione F, Capano S, Regano D, Zentilin L, Giacca M, Casanovas O, Bussolino F, Serini G, Giraudo E.

J Clin Invest. 2012 May;122(5):1832-48. doi: 10.1172/JCI58976. Epub 2012 Apr 9.

39.

Cancer: Limitations of therapies exposed.

Casanovas O.

Nature. 2012 Apr 4;484(7392):44-6. doi: 10.1038/484044a. No abstract available.

PMID:
22481354
40.

Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling.

Benedito R, Rocha SF, Woeste M, Zamykal M, Radtke F, Casanovas O, Duarte A, Pytowski B, Adams RH.

Nature. 2012 Mar 18;484(7392):110-4. doi: 10.1038/nature10908.

PMID:
22426001
41.

Exploiting pleiotropic activities of semaphorins as multi-target therapies for cancer.

Moserle L, Casanovas O.

EMBO Mol Med. 2012 Mar;4(3):168-70. doi: 10.1002/emmm.201200206. Epub 2012 Feb 10. No abstract available.

42.

Use of a mouse model of pancreatic neuroendocrine tumors to find pericyte biomarkers of resistance to anti-angiogenic therapy.

Franco M, Pàez-Ribes M, Cortez E, Casanovas O, Pietras K.

Horm Metab Res. 2011 Nov;43(12):884-9. doi: 10.1055/s-0031-1284381. Epub 2011 Sep 29.

PMID:
21960459
43.

Non-invasive monitoring of hypoxia-inducible factor activation by optical imaging during antiangiogenic treatment in a xenograft model of ovarian carcinoma.

Martinez-Poveda B, Gomez V, Alcaide-German M, Perruca S, Vazquez S, Alba LE, Casanovas O, Garcia-Bermejo ML, Peso L, Jimenez B.

Int J Oncol. 2011 Sep;39(3):543-52. doi: 10.3892/ijo.2011.1074. Epub 2011 Jun 9.

PMID:
21667025
44.

Glycolytic phenotype and AMP kinase modify the pathologic response of tumor xenografts to VEGF neutralization.

Nardo G, Favaro E, Curtarello M, Moserle L, Zulato E, Persano L, Rossi E, Esposito G, Crescenzi M, Casanovas O, Sattler U, Mueller-Klieser W, Biesalski B, Thews O, Canese R, Iorio E, Zanovello P, Amadori A, Indraccolo S.

Cancer Res. 2011 Jun 15;71(12):4214-25. doi: 10.1158/0008-5472.CAN-11-0242. Epub 2011 May 5.

45.

The adaptive stroma joining the antiangiogenic resistance front.

Casanovas O.

J Clin Invest. 2011 Apr;121(4):1244-7. doi: 10.1172/JCI46430. Epub 2011 Mar 23.

46.

Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing.

Melo S, Villanueva A, Moutinho C, Davalos V, Spizzo R, Ivan C, Rossi S, Setien F, Casanovas O, Simo-Riudalbas L, Carmona J, Carrere J, Vidal A, Aytes A, Puertas S, Ropero S, Kalluri R, Croce CM, Calin GA, Esteller M.

Proc Natl Acad Sci U S A. 2011 Mar 15;108(11):4394-9. doi: 10.1073/pnas.1014720108. Epub 2011 Feb 28. Erratum in: Proc Natl Acad Sci U S A. 2017 Jan 17;:.

47.

The use of caspase inhibitors in pulsed-field gel electrophoresis may improve the estimation of radiation-induced DNA repair and apoptosis.

Balart J, Pueyo G, de Llobet LI, Baro M, Sole X, Marin S, Casanovas O, Mesia R, Capella G.

Radiat Oncol. 2011 Jan 15;6:6. doi: 10.1186/1748-717X-6-6.

48.

Filamin B plays a key role in vascular endothelial growth factor-induced endothelial cell motility through its interaction with Rac-1 and Vav-2.

Del Valle-Pérez B, Martínez VG, Lacasa-Salavert C, Figueras A, Shapiro SS, Takafuta T, Casanovas O, Capellà G, Ventura F, Viñals F.

J Biol Chem. 2010 Apr 2;285(14):10748-60. doi: 10.1074/jbc.M109.062984. Epub 2010 Jan 28.

49.

Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.

Castillo-Avila W, Piulats JM, Garcia Del Muro X, Vidal A, Condom E, Casanovas O, Mora J, Germà JR, Capellà G, Villanueva A, Viñals F.

Clin Cancer Res. 2009 May 15;15(10):3384-95. doi: 10.1158/1078-0432.CCR-08-2170. Epub 2009 May 5.

50.

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.

Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D, Casanovas O.

Cancer Cell. 2009 Mar 3;15(3):220-31. doi: 10.1016/j.ccr.2009.01.027.

Supplemental Content

Loading ...
Support Center